Press Releases - Daiichi Sankyo US
WEBNews, Events, Updates, Breakthroughs. Journalists may direct questions to [email protected]. Or click here for direct contact information for Daiichi Sankyo U.S. Public Affairs team. Press announcements are archived by release date, searchable by topic: Email Alert
News Room - Daiichi Sankyo US
WEBDaiichi Sankyo Europe's Statement Regarding Esperion Therapeutics' Complaint. Industry Veteran, Dr. Mark Rutstein, Joins Daiichi Sankyo to Lead Global Oncology Clinical Development Program. Daiichi Sankyo, Inc. has taken measures to contribute to the overall effort to limit the spread of the virus that causes COVID-19.
Media - Daiichi Sankyo
WEBFeb 19, 2024 · Tokyo and Basking Ridge, NJ – (February 19, 2024) – Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the U.S. for the treatment of adult patients with locally advanced or metastatic nonsquamous non …
Passion for innovation. Compassion for patients. - Daiichi Sankyo US
WEBFor people affected by cancer, Daiichi Sankyo turns hope into possibility. Possibility into reality. Our collective craft is medicine. We’re transforming how cancer and other disease are treated. More than 120 year of heritage inspires us to meet new challenges.
Daiichi Sankyo and Merck Announce Global Development and ...
WEBOct 19, 2023 · Daiichi Sankyo (TSE: 4568) and Merck (known as MSD outside of the United States and Canada) (NYSE: MRK) have entered into a global development and commercialization agreement for three of Daiichi Sankyo’s DXd antibody drug conjugate (ADC) candidates: patritumab deruxtecan (HER3-DXd), ifinatamab deruxtecan (I-DXd) and raludotatug deruxtecan (R ...
U.S. News Room - Daiichi Sankyo US
WEBOct 24, 2022 · Submission based on QuANTUM-First results showing quizartinib plus chemotherapy significantly improved overall survival compared to chemotherapy alone. Tokyo and Basking Ridge, NJ – (October 24, 2022) – Daiichi Sankyo (TSE: 4568) received notification of acceptance by the U.S. Food and Drug Administration (FDA) of …
U.S. News Room - Daiichi Sankyo US
WEBDec 23, 2021 · Designed using Daiichi Sankyo’s proprietary DXd ADC technology, patritumab deruxtecan is comprised of a fully human anti-HER3 IgG1 monoclonal antibody attached to a topoisomerase I inhibitor payload (an exatecan derivative, DXd) via a stable tetrapeptide-based cleavable linker.
Daiichi Sankyo Showcases Latest Research Towards Creating New …
WEBMay 25, 2023 · Daiichi Sankyo (TSE: 4568) will present new clinical research across its oncology portfolio at the 2023 American Society of Clinical Oncology Scientific Program (#ASCO23) and the European Hematology Association Congress (#EHA23).
U.S. News Room - Daiichi Sankyo US
WEBJun 5, 2023 · Daiichi Sankyo, Inc. and American Regent, Inc., a Daiichi Sankyo Group company, today announced that the U.S. Food and Drug Administration (FDA) approved INJECTAFER® (ferric carboxymaltose injection) for the treatment of iron deficiency in adult patients with heart failure categorized as New York Heart Association class II/III …
Media - Daiichi Sankyo
WEBTURALIO™ (pexidartinib) is indicated for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery. TURALIO can cause serious and potentially fatal liver injury.